Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells Combined With Standard Therapy in Patients With Decompensated Cirrhosis

NCT05121870 is registered in ClinicalTrials.gov with Beijing 302 Hospital as lead sponsor.

NCT NCT05121870
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05121870 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Human Umbilical Cord-derived Mesenchymal Stem Cells Combined With Standard Therapy in Patients With Decompensated Cirrhosis
Lead sponsor
Beijing 302 Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
September 1, 2021
Completion date
December 31, 2023
Enrollment
240 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

decompensated cirrhosis